UBS AM
AIMT

UBS AM’s Aimmune Therapeutics AIMT Stock Holding History

UBS AM’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-38,944
Closed -$1.34M – 2623
2020
Q3 		$1.34M Sell
38,944
-462
-1% -$9.84K ﹤0.01% 1718
2020
Q2 		$658K Buy
39,406
+630
+2% +$10.7K ﹤0.01% 1994
2020
Q1 		$559K Sell
38,776
-1,944
-5% -$49.7K ﹤0.01% 1936
2019
Q4 		$1.36M Sell
40,720
-1,167
-3% -$32.6K ﹤0.01% 1762
2019
Q3 		$877K Buy
41,887
+843
+2% +$17.2K ﹤0.01% 2021
2019
Q2 		$855K Buy
41,044
+16,672
+68% +$343K ﹤0.01% 1961
2019
Q1 		$545K Buy
24,372
+3,472
+17% +$81.7K ﹤0.01% 2077
2018
Q4 		$500K Hold
20,900
– – ﹤0.01% 1996
2018
Q3 		$570K Hold
20,900
– – ﹤0.01% 2033
2018
Q2 		$562K Sell
20,900
-1,447
-6% -$44.3K ﹤0.01% 2050
2018
Q1 		$711K Buy
22,347
+13,447
+151% +$473K ﹤0.01% 1888
2017
Q4 		$337K Sell
8,900
-282,123
-97% -$9.1M ﹤0.01% 2086
2017
Q3 		$7.21M Buy
+291,023
New +$6.27M 0.01% 974

UBS AM's AIMT Position: Q4 2020 in Review

UBS AM sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 38,944 shares — an estimated $1.34M sold.

UBS AM first reported a position in AIMT in Q3 2017 and held it in 13 quarters. The position peaked at $7.21M in Q3 2017. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • UBS AM reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • UBS AM sold 38,944 Aimmune Therapeutics shares in Q4 2020, an estimated $1.34M.
  • UBS AM first reported a position in Aimmune Therapeutics in Q3 2017 and held it in 13 quarters.
  • UBS AM's Aimmune Therapeutics position peaked at $7.21M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on UBS AM's 13F filing for Q4 2020, filed 17 Feb 2021.